Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery
Launched by KUOPIO UNIVERSITY HOSPITAL · Dec 13, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help surgeons detect and remove tumor cells in patients with high-grade gliomas, which are aggressive brain tumors. The study is looking at how effective a device called the aspirate tissue monitor (ATM) is in identifying tumor cells from tissue samples taken during surgery. Currently, surgeons use a special dye that makes tumor cells glow, but some tumor cells can still be missed. By using the ATM, the hope is that surgeons will be able to see these cells more clearly, leading to better outcomes for patients and possibly reducing the need for additional surgeries.
To participate in this trial, patients must be 18 years or older and scheduled for surgery to remove a suspected high-grade glioma. It's important that patients understand they need to give their consent to take part in the study. The trial is open to all genders, but some groups, like children or pregnant individuals, are not eligible. If you or a family member is considering this trial, you can expect to receive close monitoring during the surgery and to be part of a study that aims to improve how brain tumors are treated.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient admitted to neurosurgery department for surgical resection of a suspected high-grade glioma
- • Patients aged 18 years old or older
- • Informed consent obtained
- Exclusion Criteria:
- • Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled
About Kuopio University Hospital
Kuopio University Hospital is a leading academic medical center located in Finland, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient-centered care, focusing on diverse therapeutic areas. With a commitment to enhancing treatment outcomes and improving patient quality of life, Kuopio University Hospital fosters collaboration among multidisciplinary teams, leveraging its robust infrastructure and expertise to drive medical progress and translate research findings into practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Tampere, Pirkanmaa, Finland
Kuopio, , Finland
Kuopio, Pohjois Savo, Finland
Patients applied
Trial Officials
Antti-Pekka Elomaa, Docent
Principal Investigator
Kuopio University Hospital
Joonas Haapasalo, Docent
Principal Investigator
Tampere University Hospital
Einar Vik-Mo, Professor
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported